Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 06
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Korro Bio Inc
KRRO
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$9.97
0.33
3.42%
Dern. MÀJ: Oct 2, 4:00 PM
$9.64
N/A
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Korro Bio Financials
Korro Bio (KRRO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Korro Bio Q2 EPS $(1.07) Beats $(1.31) Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.31) by 18.32 percent. This is a 60.95 percent increase over losses of $(2.74) per share from the
Benzinga Newsdesk
PRO
Korro Bio Q1 EPS $(1.69) Beats $(2.17) Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.69) per share which beat the analyst consensus estimate of $(2.17) by 22.12 percent. This is a 32.13 percent increase over losses of $(2.49) per share from the
Benzinga Newsdesk
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
Korro Bio stock rises after earnings as analysts upgrade outlook, highlight new drug candidate, and long-term growth plans.
Vandana Singh
PRO
Korro Bio Q4 EPS $(5.32) Misses $(2.05) Estimate, Sales $1.290M Beat $670.000K Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(5.32) per share which missed the analyst consensus estimate of $(2.05) by 159.39 percent. This is a 135.4 percent decrease over losses of $(2.26) per share from the
Benzinga Newsdesk
Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results
Avi Kapoor
Nasdaq Down Over 150 Points; Disney Shares Fall After Q4 Results
Avi Kapoor
